Basal and stimulation day 5 anti-Müllerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist–gonadotropin treatment
Author(s) -
Joana Peñarrubia,
Francisco Fábregues,
Dolors Manau,
Montserrat Creus,
Gemma Casals,
Roser Casamitjana,
Franciso Carmona,
Juan A. Vanrell,
Juan Balasch
Publication year - 2005
Publication title -
human reproduction
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.446
H-Index - 226
eISSN - 1460-2350
pISSN - 0268-1161
DOI - 10.1093/humrep/deh718
Subject(s) - anti müllerian hormone , intracytoplasmic sperm injection , follicular phase , ovarian reserve , controlled ovarian hyperstimulation , pregnancy , gonadotropin , assisted reproductive technology , medicine , ovulation induction , follicle stimulating hormone , ovarian hyperstimulation syndrome , pregnancy rate , hormone , in vitro fertilisation , andrology , luteinizing hormone , biology , ovulation , infertility , genetics
Anti-Müllerian hormone (AMH) has been recently proposed as a marker for ovarian ageing and poor ovarian response to controlled ovarian hyperstimulation in assisted reproduction cycles. The present study was undertaken to investigate the usefulness of baseline cycle day 3 AMH levels and AMH serum concentrations obtained on the fifth day of gonadotropin therapy in predicting ovarian response and pregnancy in women undergoing ovarian stimulation with FSH under pituitary desensitization for assisted reproduction.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom